首个非注射的胰岛素Oral—lyn
【关键词】胰岛素制剂 Oral 厄瓜多尔 非注射 生物技术公司 2型糖尿病 口腔喷雾剂 糖尿病患者 自己注射 顺应性
【文 摘】首个非注射的胰岛素制剂,Generex生物技术公司的口腔喷雾剂Oral—lyn(Oralin)在厄瓜多尔批准用于治疗1型和2型糖尿病,给每日需要自己注射的糖尿病患者带来了方便,改善了顺应性。
口腔喷入型胰岛素显示有用 2009年10月23日(蒙特娄) -根据发表于国际糖尿病联盟(国际糖尿病联合会,以色列国防军)第20届世界糖尿病研讨会的研究,每天经口腔喷入12个单位的胰岛素,有助于葡萄糖耐受异常(糖耐量低减)病患维持可接受的血糖值。这种胰岛素给药模式,为第1和第2型糖尿病的非注射型胰岛素给药方式带来新希望。 发表人,第一作者尼古拉那不勒斯博士向Medscape糖尿病和内分泌表示,我们实验新的胰岛素给药途径,因为糖尿病患最重要的问题是使用注射剂,这是胰岛素治疗的最大限制,并非所有病患都接受注射剂,注射时会痛且比较难管理。那不勒斯博士来自义大利罗马生物医学生大学内分泌与代谢科。 【人类胰岛素口腔喷剂】 确认为糖耐量低减的31名病患,随机分派接受分成2个剂量的4,6或12个单位的口腔喷入型胰岛素。在标准的75克口服葡萄糖耐受测试前给予1个剂量,测试后30分钟给予另一次剂量。每一喷相当于1单位的胰岛素。之后在30,60,90,120和180分钟时检测葡萄糖和胰岛素值。 【12喷获得较低的血中葡萄糖值】 塔拉哈西(佛罗里达州首府)佛罗里达大学医学院小儿内分泌专家拉里长迪伯医师表示认同,认为发现其他的胰岛素给药途径是重要的。他表示,胰岛素给药是糖尿病患的一大问题。你必须克服恐惧,还有那些未按医嘱用药也还不至于致命的人。漏给胰岛素是第1和第2型糖尿病的重要问题之一。 【口腔给药的潜力】 口腔喷剂已经在第1和第2型糖尿病的短期试验中成功检测。目前正在进行长期研究,那不勒斯博士等人目前对糖耐量低减病患进行1个这类型的长期研究。 那不勒斯博士的研究接受雷克斯赞助。迪伯医师宣告没有相关财务关系。 国际糖尿病联盟(IDF)为第20届世界糖尿病研讨会。摘要Ḏ- 0965。发表于2009年10月21日。 Generex Oral-Lyn Generex Oral-lyn™, is an insulin spray for the treatment of Type I and Type II diabetes. Generex Oral-lyn™ is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin and is conveniently delivered to the membranes of the oral cavity by a simple asthma-like device with no pulmonary (lung) deposition. As a pain-free and convenient method of insulin delivery, Generex Oral-lyn™ will allow individual patients to "fine tune" and then maintain their metabolism resulting in an improved quality of life. Accordingly, Generex Oral-lyn™ provides the opportunity for the establishment of a new and more efective diabetes treatment paradigm. 口腔喷入型胰岛素说明书 Drug (Brand / Generic)
Oral-Lyn
Company / Licensee
Generex Biotechnology
Therapy Class
Insulins
Product Description
Oral spray formulation of human insulin
Current Indication
Type 2 diabetic patients
Market Sector
Diabetes
Development Status
Approved Ecuador; phase III Europe and North America
Under development by Canadian company Generex Biotechnology, Oral-Lyn is an oral spray formulation of human insulin indicated for the treatment of type 1 and 2 diabetes. Having secured regulatory approval in 2005 for clinical use of Oral-Lyn in type 2 diabetics in Ecuador, the company is keen to progress phase III trials in the major North American and European markets, where it hopes eventually to achieve comparable success The announcement to start Phase III for Oral-Lyn in North America was made on 7 April 2008, beginning with patient screening. The first screening was carried out in Texas in late March 2008. Other clinical sites taking part in the study are located in Maryland, Minnesota, California and in the province of Alberta in Canada. Non-injectable insulins may improve complianceAt present diabetics who require insulin to keep their blood sugar levels under tight control (target HbA1c levels of <7%) have to administer it by injection. The need for regular daily injections is a major drawback for diabetic patients and can reduce compliance with treatment. Considerable research effort has been devoted to the development of alternative modes of insulin delivery which can deliver insulin safely and effectively without the need for injection. Various alternatives to injectable insulin have been investigated including:
Generex's Oral-Lyn is a liquid formulation of human insulin that is sprayed into the mouth using its proprietary RapidMist device. In the mouth the insulin is absorbed via the buccal mucosa, an area with a rich vasculature. Generex believes that Oral-Lyn will provide an effective alternative to prandial insulin injections and improve patient compliance with insulin therapy. "The need for regular daily injections is a major drawback for diabetic patients and can reduce compliance with treatment."
Evidence of efficacy in diabetic patientsApproval of Oral-Lyn by the Ecuadorian Ministry of Public Health was based on data from clinical trials conducted in Ecuador which involved more than 250 patients with type 2 diabetes. These showed that Oral-Lyn had comparable efficacy to prandial insulin injections in this patient population. The company is also hoping to extend use of Oral-Lyn in Ecuador to type 1 diabetic patients and has already initiated a six-month study of its safety and efficacy in adolescent and young adult patients with type1 diabetes. An earlier short-term study, in which Oral-Lyn was compared with short-acting subcutaneously injected pre-prandial insulin (Humulin), was considered successful. In this study Oral-Lyn was taken both before and after each meal. The real test of the product's viability, however, will come from large-scale trials involving several thousand patients that will be required by regulatory authorities in North America and Europe. On 6 August 2008, Generex recieved approval to conduct an Oral-Lyn trial on patients diagnosed with or prone to developing impaired glucose tolerance. The approval was recieved from the Ethics Committe at University Campuse Bio Medico, Rome. The study was to help determine whether the glucose levels of patients drop when they are using Oral-Lyn. Plans are underway for Phase III trials in Canada and Europe to be followed by similar large-scale studies in the US. On 11 March 2008 Generex announced that the labelling and packaging of cannisters for Oral-Lyn had been completed. The cannisters will be used for Phase III clinical trials in the US, Canada and Ukraine. Diabetes represents a rapidly growing problem Estimates from the World Health Organisation suggest that 150 million or more people have diabetes, of which type 2 accounts for the vast majority of cases. Worldwide, the costs associated with the treatment of diabetes and its complications are estimated to exceed $200 billion annually. Adverse lifestyle changes which have seen an explosion in the incidence of obesity, an important risk factor for type 2 diabetes, are contributing to the continual rise in the number of new cases that occur each year. By 2025, prevalence of diabetes is expected to have more than doubled from today's figures. "Generex's Oral-Lyn is a liquid formulation of human insulin that is sprayed into the mouth."
Left untreated or poorly controlled, diabetes can lead to serious complications such as retinopathy, cardiovascular disease, nephropathy, neuropathy and peripheral vascular disease as well as premature death. Insulin injections revolutionised the treatment of diabetes when first introduced into clinical practice in the 1920s. The advent of non-injectable insulins, such as Oral-Lyn, have the potential to be just as revolutionary and to make regular insulin therapy much more acceptable to diabetic patients. Marketing commentary In addition to all type 1 diabetic patients, for whom insulin is essential therapy, there are about 40-50 million type 2 diabetic patients who also need insulin to control their blood sugar levels effectively. However, the thought of having to self-inject several times a day leads many patients to fail to take their insulin treatment regularly, exposing them to the risk of diabetes-related complications. Insulin therapies have evolved over recent years to include rapid-acting insulin analogues, analogue mixtures and long-acting insulin analogues. Non-injectable insulins are now poised to enter the market, with analysts predicting that these new insulin formulations could achieve sales in excess of $5bn by the end of the decade. Generex has recieved approval for commercial sale of Oral-Lyn in several countries. In India, approval was obtained in November 2007. The first commercial order was made by Generex's Indian distributor Shreya Life Sciences in March 2008 for 210,000 cannisters of Oral-Lyn. On 1 April 2008, Generex signed a licence and distribution agreement with SciGen. Under this agreement, SciGen will acquire approvals for importing, marketing, distributing and selling Oral-Lyn in China, Hong Kong, Indonesia, South Korea, Malaysia, the Philippines, Singapore, Thailand and Vietnam. SciGen will use its own recomnibant human insulin product for the sale of Oral-Lyn in these countries. On 14 May 2009, Oral-Lyn was launched in Lebanon by Benta SAL. It is available on the market as a box containing one canister and one actuator. The cannister contains 400IU of recombinant human insulin, while an actuator is a device that is used for managing the drug.
|
Oral—lyn口腔胰岛素喷雾剂-首个治疗1型和2型糖尿病新药简介:首个非注射的胰岛素Oral—lyn
【关键词】胰岛素制剂 Oral 厄瓜多尔 非注射 生物技术公司 2型糖尿病 口腔喷雾剂 糖尿病患者 自己注射 顺应性
【文 摘】首个非注射的胰岛素制剂,Generex生物技术公司的 ... 关键字:Oral—lyn口腔胰岛素喷雾剂
责任编辑:admin |
最新文章更多推荐文章更多热点文章更多
|